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Abstract
The increasing in the life span of patients with major thalassemia should be followed by increased quality of life. 
There are factors which can affect growth retardation in these patients. The aim of this study was to find out the risk 
factors for growth retardation in patients with major thalassemia. An analytical study with cross-sectional design 
was conducted at Pediatric Thalassemia Clinics of Dr.Hasan Sadikin Hospital, Bandung, in June to July 2006. The 
subjects of this study were patients with major thalassemia. Inclusion criteria’s were age under 14 years old, had 
no chronic diseases like tuberculosis, cerebral palsy with complete medical records. Risk factors were the timing 
of diagnosis, initial and dose of deferoxamine, volume of transfused blood, mean pretransfusion hemoglobin level, 
family income, and age. Antropometric measurement indices were used to assess the growth which expressed in Z 
score. Growth evaluated based on height/age (H/A) and growth retardation if H/A <-2 SD.  Risk factors for growth 
retardation were analyzed separately using chi-square test and odds ratio (OR) with 95% confidence interval (CI). 
Then they were analyzed simultaneously with logistic regression method. Subjects consisted of 152 patients with 
major thalassemia. Seventy three thalassemia patients were stunted. Analysis showed that age (OR: 5.42, 95% CI: 
2.32–12.65, p <0.001), dosage of deferoxamine (OR: 4.0, 95% CI: 1.29–12.41, p: 0.016), and family income (OR: 
2.32, 95% CI: 1.06–5.06, p: 0.036) were risks factors for growth retardation. Conclusion, risk factors for growth 
retardation in major thalassemia are age, dosage of deferoxamine, and family income. [MKB. 2011;43(1):21–5].
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Faktor Risiko terhadap Gangguan Tumbuh pada Thalassemia Mayor
Abstrak
Bertambahnya harapan hidup penderita thalassemia, seyogianya diikuti dengan kualitas hidup seperti anak normal. 
Terdapat berbagai faktor risiko yang mempengaruhi terjadinya gangguan tumbuh pada penderita thalassemia 
mayor. Tujuan penelitian ini untuk mengetahui berbagai faktor risiko terjadinya gangguan tumbuh pada penderita 
thalassemia mayor. Penelitian ini merupakan penelitian analitik dengan rancangan cross sectional di Poliklinik 
Anak thalassemia Dr. Hasan Sadikin, Bandung, pada bulan Juni–Juli 2006. Subjek penelitian ini adalah penderita 
thalassemia mayor. Kriteria inklusi adalah penderita berusia <14 tahun, tidak mempunyai penyakit kronik 
seperti tuberkulosis, palsi serebral, dan rekam medis yang lengkap. Faktor risiko adalah usia saat penegakan 
diagnosis, usia mulai menggunakan desferoksamin, dosis desferoksamin, volume darah yang telah diterima, kadar 
hemoglobin rata-rata sebelum transfusi, penghasilan keluarga, dan usia penderita. Dengan antropometri akan 
ditentukan pertumbuhan berdasarkan skor-Z. Pertumbuhan dinilai dari indeks  tinggi badan/usia dan penderita 
yang mengalami gangguan tumbuh  bila tinggi badan/usia <-2 SD.  Faktor risiko gangguan tumbuh dianalisis 
menggunakan uji ki kuadrat dan rasio odds (RO) dengan interval kepercayaaan (IK) 95%, selanjutnya dilakukan 
analisis dengan metode regresi logistik. Subjek terdiri atas 152 penderita thalassemia mayor. Terdapat 73 penderita 
yang mengalami gangguan tumbuh. Hasil analisis menunjukkan usia penderita  (RO 5,42; IK 95%: 2,32–12,65, 
p <0, 001), dosis desferoksamin (RO 4,0; IK95%:1,29–12,41, p: 0,016), dan penghasilan keluarga (RO 2,32; IK 
95%:1,06–5,06, p: 0,036). merupakan faktor risiko terjadinya gangguan tumbuh. Simpulan, faktor risiko terjadinya 
gangguan tumbuh pada thalassemia mayor adalah usia, dosis desferoksamin, dan penghasilan keluarga. 
[MKB. 2011;43(1):21–5].
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Introduction 
The increasing in the life span of patients with 
thalassemia should be followed by increased 
quality of life but almost all thalassemia patients 
had growth retardation.1-4 Growth retardation 
in patients with thalassemia major is caused 
by multiple factors such as tissue hypoxia and 
iron overload. Nutrition is another important 
factor for growth.5,6 Growth retardation can be 
evaluated based on height/age (H/A) <-2 SD 
(stunted).7,8 Saxena5 found five risk factors: 
low hemoglobin pretransfusion, high feritin, 
inoptimal iron chelating agent, poor socio 
economic background, and increasing age to 
growth retardation in thalassemia major patients. 
Study in Iran found there is association of initial 
deferoxamine treatment, dosage of deferoxamine, 
age, and maintenance level of hemoglobin <8.5 
g/dL with growth retardation.9,10 Andayani et al11 
found association between volume of transfused 
blood and growth retardation. Until this time, 
there has never been any study involving all 
seven factors simultaneously.
The aim of this study was to know the risk 
factors for growth retardation (the timing of 
diagnosis, initial deferoxamine treatment and 
dosage of deferoxamine, volume of transfused 
blood, mean pretransfusion hemoglobin level, 
family income, and age) in patients with major 
thalassemia. The study was initiated with the 
approval of Institutional Ethics Committee of 
Medical School, University of Padjadjaran, Hasan 
Sadikin Hospital Bandung, Indonesia and written 
informed consent of either parents was taken for 
inclusion of children.
Methods
An analytical study with cross-sectional design 
was conducted at the Clinics of Pediatric 
Thalassemia of Hasan Sadikin Hospital, Bandung. 
The subjects of this study were patients with major 
thalassemia visiting the clinic in June to July 
2006.  Inclusion criteria’s were age under 14 years 
old, had no chronic diseases like tuberculosis, 
cerebral palsy, congenital heart diseases, and has 
complete medical records. This study involved 
only 152 subjects recruited consecutively due to 
limited time and fund. 
Risk factors were the timing of diagnosis, 
initial and dosage deferoxamine treatment, 
volume of transfused blood, mean pretransfusion 
hemoglobin level, family income, and age. 
Outcome in this study was stunted.7,8
   Anthropometric measurement indices were 
Table 1 Characteristics Major Thalassemia Patient’s
Characteristics
Sex
     Male
     Female
Age (months)
     Range 
Weight (kg)
     SD
     Range
Height (cm)
     SD
     Range
The timing of diagnosis (months)
     Range
Initial deferoxamine treatment (years)
     Range
Dosage of  deferoxamine
     Optimal
      In optimal
Volume of transfused blood (mL)
      SD
      Range
Mean pretransfusion hemoglobin level (g/dL)
      SD
      Range
Family income (rupiah)
      Range
78 (51.3%)
74 (48.7%)
11–157
5.2
7.1–32
15.5
66–145
1–15
1–12.5
24 (16.9%)
118 (83.1%)
12,754
500–60,000
1.14
5–9
100,000–5,000,000
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used to assess the growth which was expressed 
in Z-score. Growth evaluated based on H/A <-2 
SD (stunted). Risk factors for growth retardation 
were identified by taking history and based on 
medical records.7,8
Patients with thalassemia major diagnosed 
by electrophoresis of blood. Timing of diagnosis 
was age the patients diagnosed thalassemia, 
divided into two groups, <12 months and ≥12 
months. Initial deferoxamine treatment was age 
at the first deferoxamine uses, divided into two 
groups,  <3 or >10 years and 3–10 years. Dosage 
of deferoxamine consisteded of optimal dosage 
and inoptimal dosage. Volume of transfused blood 
was divided into two groups, <20,000 mL and 
≥20,000 mL. Mean pretransfusion hemoglobin 
level were mean hemoglobin level patients before 
transfusion, divided into two groups, <8.5 g/dL 
and ≥8.5 g/dL. Family income evaluated based 
on income/month, divided into two groups, < 
850,000 and ≥850,000 rupiah.
Risk factors for growth disturbances and 
nutritional status were analyzed separately using 
chi-square test and odds ratio (OR) with 95% 
confidence interval (CI). They were analyzed 
concurrently with logistic regression method.12 
Data were analyzed using SPSS version 13.00 for 
windows SPSS inc., Chicago-Illinois, USA. 
Results
There were 152 patients with thalassemia major 
enrolled in this study. Seventy three thalassemia 
patients were stunted. Characteristics of patients 
are shown in Table 1.
Based on univariate analysis, association of 
various risk factors with stunted were age >10 
years, initial deferoxamine treatment  <3 or >10 
years, in optimal deferoxamine dosage, volume of 
transfused blood ≥20,000 mL, mean transfusion 
hemoglobin level <8.5 g/dL and family income < 
850,000 rupiah shown in Table 2.
Logistic regression showed that age >10 
Table 2 Association of Risk Factors to Growth Retardation
Variable Stunted (73) Normal (79) X2 p Value OR
Age (years)
>10 34 10 21.22 <0.001* 2.14
(1.59–2.88)<10 39 69
Timing of diagnosis  (months)
>12     22 17 1.48 0.224 1.25
(0.88–1.76)<12 51 62
Initial deferoxamine treatment (years)
<3 or >10 26 13 6.49 0.011 1.56
(1.14–2.14)3–10 44 59
Deferoxamine dosage
Inoptimal    65 53 9.36 0.002* 2.64
(1.19–5.87)Optimal  5 19
Volume of transfused blood (mL)
>20,000 44 21 17.59 <0.001 2.03
(1.44–2.86)<20,000 29 58
Mean pretransfusion hemoglobin level (g/dL)
<8.5 55 42 8.08 0.004 1.73
(1.14–2.63)>8.5 18 37
Family income (rupiah)
<850,000 54 43 6.26 0.012 1.61
(1.08–2.42)>850,000 19 36
*X2: Chi-square, OR: Odds Ratio
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years old (odds ratio 5.42, p <0.001), in optimal 
deferoxamine dosage (odds ratio 4, p=0.016), and 
family income < 850,000 rupiah (odds ratio 2.32, 
p=0.036) were risk factors for stunted shown in 
Table 3.
Discussion
This study was expected to show risk factors for 
growth retardation in thalassemia patients. There 
were 152 children enrolled in this study consisted 
of 78 males (51.3%) and 74 females (48.7%). 
We found no significant difference in sex gender 
in association with growth retardation. It was 
in accordance with study in Iran, Turkey, and 
Hongkong.13-15
In this study growth retardation were 
assessed based on height/age. Our study showed 
73 (48.0%) were stunted. These data was similar 
with previous report that showed almost all 
thalassemia patients were stunted. Karamifar et 
al14  reported prevalence of stunted  as 64% in 
patients with major thalassemia. In other study, 
Karamifar et al15 concluded 62.9% of girls and 
69% of boys were less than 2 SD below mean 
for normal height. Asadi Pooya et al9  reported 
the height for age in 63% of patients with major 
thalassemia were lower than the 5th percentile. 
The exact mechanism of growth retardation in 
children with thalassemia major is unclear and 
seems to be multifactorial.5,9, 14-16
Saxena5 found five risk factors: low hemoglobin 
pre transfusion, high feritin, inoptimal iron chelating 
agent, poor socio economic background, and 
increasing age to growth retardation in thalassemia 
major patients. In Iran found an association of 
initial deferoxamine treatment, dosage, age, and 
maintenance level of hemoglobin <8.5 g/dL with 
growth retardation.9,10
In our study, only three of seven risk factors 
for stunted were significant. There were three 
risk factors for stunted such as age >10 years 
old, inoptimal deferoxamine dosage, and family 
income <850,000 rupiah. If three risk factors 
were found together, the risk for stunted raised 
to 20.5%. 
Similar with previous study from Pignatti 
et al17 that found stunted was more frequent in 
pubertal patients. This was despite the fact that 
in pubertal children there may be a reduced 
growth spurt with marked deceleration and iron 
overload in endocrine glandular. The effect of in 
optimal deferoxamine dosage was similar with 
study from Saxena5 which showed that growth 
retardation in India were led to high feritin. 
Level family income <850,000 rupiah was risk 
factor for stunted, the result was similar with 
study from Saxena5. Poor social economic states 
based on family income implies poor nutrition, 
hygiene, and social atmosphere.5 Most of our 
patients suffered from poor control, inoptimal 
deferoxamine dosage, and low economic status. 
In conclusion risk factors for growth retarda-
tion are age >10 years old, in optimal deferoxamine 
dosage, and family income <850,000 rupiah. The 
timing diagnosis, initial deferoxamine treatment, 
mean pretransfusion hemoglobin level, and 
volume of transfused blood clinically seemed 
to be the influencing factors, but the results was 
Table 3 Risk Factors To Gowth Retardation In Patients with Major Thalassemia
Variable Coefficient β SE (β) p* Value OR (95% CI)
Age >10 years old 1.690 0.432 <0.001 5.422
(2.323–12.653)
Initial deferoxamine treatment  <3 or >10  years old 0.746 0.463 0.107 2.108
(0.851–5.224)
Inoptimal deferoxamine dosage 0.386 0.578 0.016 4.0
(1.289–12.413)
Volume of tranfused blood  >20,000 mL 0.418 0.465 0.368 1.519
(0.611–3.781)
Mean pre transfusion hemoglobin level <8.5 g/dL 0.275 0.420 0.513 1.317
(0.578–2.999)
Family income <850,000 0.841 0.400 0.036 2.318
(1.058–5.075)
Constanta  -1.671
*Log regression
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not statistically significance, so they need to be 
explored further with larger sample.
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